EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Jing Gao, Lei Yang, Shumin Lei, Feng Zhou, Huijun Nie, Bo Peng, Tianfeng Xu, Xiaohua Chen, Xiaobao Yang, Chunquan Sheng, Yu Rao, Kanyi Pu und 3 weitere

Science Bulletin · 2023-05 · 68 (10) · 1069-1085

DOI: 10.1016/j.scib.2023.04.028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Bulletin, 2023-05. Verfasst von Jing Gao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 160 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The proteolysis targeting chimeras (PROTACs) approach has attracted extensive attention in the past decade, which represents an emerging therapeutic modality with the potential to tackle disease-causing proteins that are historically challengeable for conventional small molecular inhibitors. PROTAC harnesses the endogenic E3 ubiquitin ligase to degrade protein of interest (POI) via ubiquitin-proteasome system in a cycle-catalytic manner. The event-driven pharmacology of PROTAC is poised to pursue those targets that are conventionally undruggable, which enormously extends the space of drug development. Furthermore, PROTAC has the potential to address drug resistance of small molecular inhibitors by degrading the whole POI. Nevertheless, PROTACs display high-efficiency and always-on properties to degrade POI, they may cause severe side effects due to an "on-target but off-tissue" protein degradation profile at the undesirable tissues and cells. Given that, the stimuli-activatable PROTAC prodrugs have been recently exploited to confine precise protein degradation of the favorable targets, which may conquer the adverse effects of PROTAC due to uncontrollable protein degradation. Herein, we summarized the cutting-edge advances of the stimuli-activatable PROTAC prodrugs. We also overviewed the progress of PROTAC prodrug-based nanomedicine to improve PROTAC delivery to the tumors and precise POI degradation in the targeted cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNeoplasmsHumansProteolysisProteasome Endopeptidase ComplexProteins

Stichwörter der Autor:innen

Combinatory therapyNanomedicinePROTACPrecise protein degradationStimuli-activatable prodrug

Substanzen

ProdrugsProteasome Endopeptidase ComplexProteins

Autor:innen und Institutionen

  • Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Center of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Information Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Center of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Universit…
  • Gluetacs Therapeutics (Shanghai) Co., Ltd. Shanghai 201306, China.
  • School of Pharmacy, Second Military Medical University, Shanghai 200433, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., Rao, Y., Pu, K., Jin, J., Xu, Z., & Yu, H. (2023). Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Science Bulletin, 68(10), 1069-1085. https://doi.org/10.1016/j.scib.2023.04.028

Vancouver

Gao J, Yang L, Lei S, Zhou F, Nie H, Peng B, et al. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Science Bulletin. 2023;68(10):1069-1085. doi:10.1016/j.scib.2023.04.028

BibTeX
@article{Gao2023,
  author = {Gao, Jing and Yang, Lei and Lei, Shumin and Zhou, Feng and Nie, Huijun and Peng, Bo and Xu, Tianfeng and Chen, Xiaohua and Yang, Xiaobao and Sheng, Chunquan and Rao, Yu and Pu, Kanyi and Jin, Jian and Xu, Zhiai and Yu, Haijun},
  title = {Stimuli-activatable PROTACs for precise protein degradation and cancer therapy},
  journal = {Science Bulletin},
  year = {2023},
  volume = {68},
  number = {10},
  pages = {1069--1085},
  doi = {10.1016/j.scib.2023.04.028}
}
Kostenlos starten →